Related references
Note: Only part of the references are listed.Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT
Arnon Nagler et al.
BONE MARROW TRANSPLANTATION (2021)
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT
Noga Shem-Tov et al.
LEUKEMIA (2020)
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
Elias Jabbour et al.
LEUKEMIA RESEARCH (2020)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
David Marks et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Sebastian Giebel et al.
ANNALS OF HEMATOLOGY (2019)
Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Elias Jabbour et al.
BLOOD (2019)
The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia
Anna Czyz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
Jiri Pavlu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Sebastian Giebel et al.
BONE MARROW TRANSPLANTATION (2019)
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
HEMATOLOGY (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Mar row Transplantation
Sebastian Giebel et al.
HAEMATOLOGICA (2017)
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Mar row Transplantation
Sebastian Giebel et al.
HAEMATOLOGICA (2017)
MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation
Laura Godfrey et al.
EXPERIMENTAL HEMATOLOGY (2017)
Blinatumomab-induced lineage switch of B-ALL with t(4:11) (q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis
C. L. Haddox et al.
BLOOD CANCER JOURNAL (2017)
Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
Marina Lafage-Pochitaloff et al.
BLOOD (2017)
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy
Estelle Balducci et al.
ANNALS OF HEMATOLOGY (2017)
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Viktoras Frismantas et al.
BLOOD (2017)
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Seong Lin Khaw et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy
Ahmad Rayes et al.
PEDIATRIC BLOOD & CANCER (2016)
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby et al.
NATURE COMMUNICATIONS (2016)
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Nathalie Dhedin et al.
BLOOD (2015)
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
Anna K. Andersson et al.
NATURE GENETICS (2015)
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
Juliana M. Benito et al.
CELL REPORTS (2015)
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheira Beldjord et al.
BLOOD (2014)
Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
S. Nishiwaki et al.
ANNALS OF ONCOLOGY (2013)
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts
Sabina Chiaretti et al.
HAEMATOLOGICA (2013)
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial
David I. Marks et al.
HAEMATOLOGICA (2013)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome
Michael B. Tomblyn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation
Blaine W. Robinson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia.: The Polish Adult Leukemia Group ALL 4-2002 MRD Study
Jerzy Holowiecki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Anthony V. Moorman et al.
BLOOD (2007)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Share Paper
